Andrew Yee, Md

This study tests whether adding daratumumab to a standard three-drug regimen can shrink tumors in people whose multiple myeloma has returned or stopped responding to prior treatments. About 43 adults aged 18 to 80 will receive the four drugs in cycles. The main goal is to see how…